<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00550953</url>
  </required_header>
  <id_info>
    <org_study_id>1235.14</org_study_id>
    <nct_id>NCT00550953</nct_id>
  </id_info>
  <brief_title>Filtered Trial for Telmisartan 40mg Non-responder</brief_title>
  <official_title>Filtered Trial for Telmisartan 40mg Non-responder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to:

      Demonstrate that a fixed-dose combination of telmisartan 40 mg plus amlodipine 5 mg is
      superior to telmisartan 40 mg alone in patients with essential hypertension and inadequately
      controlled with telmisartan 40 mg monotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in Seated Diastolic Blood Pressure From Baseline to 8 Weeks</measure>
    <time_frame>Baseline and 8 Weeks</time_frame>
    <description>The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease in Seated Systolic Blood Pressure From Baseline to 8 Weeks</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Seated Trough Diastolic Blood Pressure Less Than 90 mmHg at 8 Weeks (0 Percent at Baseline)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Seated trough diastolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Seated Trough Systolic Blood Pressure Less Than 140 mmHg at 8 Weeks (0 Percent at Baseline)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Seated trough systolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Achieved an Adequate Response in Seated Trough Diastolic Blood Pressure at 8 Weeks (0 Percent at Baseline)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Adequate response defined that seated trough diastolic blood pressure was &lt;90 mmHg or decreased from reference baseline by &gt;=10 mmHg at 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Achieved an Adequate Response in Seated Trough Systolic Blood Pressure at 8 Weeks (0 Percent at Baseline)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Adequate response defined that seated trough systolic blood pressure was &lt;140 mmHg or decreased from reference baseline by &gt;=20 mmHg at 8 weeks (0 percent at baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Optimal, Normal or High Normal Blood Pressure at 8 Weeks (0 Percent at Baseline)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Optimal, normal, high normal blood pressure were defined as follows:
Optimal: Systolic blood pressure (SBP) &lt; 120 mmHg and diastolic blood pressure (DBP) &lt; 80 mmHg
Normal: SBP &gt;= 120 mmHg or DBP &gt;= 80 mmHg and SBP &lt; 130 mmHg and DBP &lt; 85 mmHg
High normal: SBP &gt;= 130 mmHg or DBP &gt;= 85 mmHg and SBP &lt; 140 mmHg and DBP &lt; 90 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Relevant Abnormalities for Changes in Blood Pressure and Pulse Rate Due to Position Change, Seated Pulse Rate, Laboratory Parameters and ECG</measure>
    <time_frame>First administration of randomised treatment to 24 hours post last dose of randomised treatment</time_frame>
    <description>Clinical relevant abnormalities for changes in blood pressure and pulse rate due to position change, seated pulse rate, laboratory parameters and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.</description>
  </secondary_outcome>
  <enrollment type="Actual">314</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telmisartan+amlodipine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telmisartan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Essential hypertensive patients who satisfying non-responder criteria

          2. Male or Female

          3. Age 20 years or older

          4. Outpatient

        Exclusion Criteria:

          1. Taking four or more anti-hypertensive medications

          2. Secondary hypertension

          3. Mean seated diastolic blood pressure (DBP) &gt; 114 mmHg and/or mean seated systolic
             blood pressure (SBP) &gt; 200 mmHg at Visit 1, 2, 3, or 4, or mean seated DBP &lt; 90 mmHg
             at Visit 3.

          4. Sustained ventricular tachycardia or other clinically relevant cardiac arrhythmias

          5. Congestive heart failure patients with the New York Heart Association (NYHA)
             functional class III-IV

          6. History of myocardial infarction or cardiac surgery within last 6 months

          7. History of coronary artery bypass graft or percutaneous coronary intervention (PCI)
             within last 3 months

          8. History of unstable angina within last 3 months

          9. Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant
             stenosis of aortic or mitral valve

         10. History of stroke or transient ischemic attack within last 6 months

         11. History of sudden exacerbation of renal function with angiotensin II receptor blockers
             (ARBs) or angiotensin converting enzyme (ACE) inhibitors, or patients with post-renal
             transplant or post-nephrectomy

         12. Experienced characteristic symptoms of angioedema during treatment with ARBs or ACE
             inhibitors

         13. Known hypersensitivity to any component of the investigational drug , or a known
             hypersensitivity to dihydropyridine -derived drugs

         14. Hepatic and/or renal dysfunction

         15. Diagnosed biliary atresia or cholestasis

         16. Hyperkalemia

         17. Dehydration

         18. Sodium deficiency

         19. Chronic administration of high doses of acidic nonsteroidal anti-inflammatory drugs
             (NSAIDs)

         20. Patients who cannot change to the restricted administration and dosage during study
             period

         21. Pre-menopausal women who meet any one of the following 1 - 3:

               -  Pregnant or possibly pregnant (1)

               -  Nursing (2)

               -  Desire to become pregnant during study period (3)

         22. Drug or alcohol dependency

         23. Complication of malignant tumour or a disease requiring immunosuppressants

         24. Compliance of &lt; 80% or &gt; 120% during the run-in period

         25. Receiving any investigational therapy within 3 months

         26. Judged to be inappropriate by the investigator or the sub-investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1235.14.002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chofu, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.14.003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Musashino, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.14.005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nishi-ku, Hiroshima, Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.14.004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.14.001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shinjuku-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2007</study_first_submitted>
  <study_first_submitted_qc>October 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2007</study_first_posted>
  <results_first_submitted>November 12, 2009</results_first_submitted>
  <results_first_submitted_qc>January 7, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 2, 2010</results_first_posted>
  <last_update_submitted>December 12, 2013</last_update_submitted>
  <last_update_submitted_qc>December 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
          <description>T40/A5 tablet, oral, once daily in the morning</description>
        </group>
        <group group_id="P2">
          <title>Telmisartan 40 mg Monotherapy</title>
          <description>A5 capsule, oral, once daily in the morning</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="156"/>
                <participants group_id="P2" count="158"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="150"/>
                <participants group_id="P2" count="152"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not able to visit the site</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
          <description>T40/A5 tablet, oral, once daily in the morning</description>
        </group>
        <group group_id="B2">
          <title>Telmisartan 40 mg Monotherapy</title>
          <description>A5 capsule, oral, once daily in the morning</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="156"/>
            <count group_id="B2" value="158"/>
            <count group_id="B3" value="314"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.4" spread="9.1"/>
                    <measurement group_id="B2" value="55.5" spread="10.2"/>
                    <measurement group_id="B3" value="55.5" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Decrease in Seated Diastolic Blood Pressure From Baseline to 8 Weeks</title>
        <description>The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.</description>
        <time_frame>Baseline and 8 Weeks</time_frame>
        <population>Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
            <description>T40/A5 tablet, oral, once daily in the morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40 mg Monotherapy</title>
            <description>A5 capsule, oral, once daily in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Decrease in Seated Diastolic Blood Pressure From Baseline to 8 Weeks</title>
          <description>The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.</description>
          <population>Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.49" spread="0.63"/>
                    <measurement group_id="O2" value="5.47" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.82</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.41</ci_lower_limit>
            <ci_upper_limit>9.63</ci_upper_limit>
            <estimate_desc>Difference calculated as telmisartan 40 mg plus amlodipine 5 mg fixed-dose combination minus telmisartan 40 mg monotherapy</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Decrease in Seated Systolic Blood Pressure From Baseline to 8 Weeks</title>
        <description>The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
            <description>T40/A5 tablet, oral, once daily in the morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40 mg Monotherapy</title>
            <description>A5 capsule, oral, once daily in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Decrease in Seated Systolic Blood Pressure From Baseline to 8 Weeks</title>
          <description>The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.</description>
          <population>Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.86" spread="0.86"/>
                    <measurement group_id="O2" value="6.51" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Seated Trough Diastolic Blood Pressure Less Than 90 mmHg at 8 Weeks (0 Percent at Baseline)</title>
        <description>Seated trough diastolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake</description>
        <time_frame>8 weeks</time_frame>
        <population>Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
            <description>T40/A5 tablet, oral, once daily in the morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40 mg Monotherapy</title>
            <description>A5 capsule, oral, once daily in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Seated Trough Diastolic Blood Pressure Less Than 90 mmHg at 8 Weeks (0 Percent at Baseline)</title>
          <description>Seated trough diastolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake</description>
          <population>Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.4"/>
                    <measurement group_id="O2" value="46.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Seated Trough Systolic Blood Pressure Less Than 140 mmHg at 8 Weeks (0 Percent at Baseline)</title>
        <description>Seated trough systolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake</description>
        <time_frame>8 weeks</time_frame>
        <population>Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
            <description>T40/A5 tablet, oral, once daily in the morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40 mg Monotherapy</title>
            <description>A5 capsule, oral, once daily in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Seated Trough Systolic Blood Pressure Less Than 140 mmHg at 8 Weeks (0 Percent at Baseline)</title>
          <description>Seated trough systolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake</description>
          <population>Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.2"/>
                    <measurement group_id="O2" value="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Achieved an Adequate Response in Seated Trough Diastolic Blood Pressure at 8 Weeks (0 Percent at Baseline)</title>
        <description>Adequate response defined that seated trough diastolic blood pressure was &lt;90 mmHg or decreased from reference baseline by &gt;=10 mmHg at 8 weeks</description>
        <time_frame>8 weeks</time_frame>
        <population>Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
            <description>T40/A5 tablet, oral, once daily in the morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40 mg Monotherapy</title>
            <description>A5 capsule, oral, once daily in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Achieved an Adequate Response in Seated Trough Diastolic Blood Pressure at 8 Weeks (0 Percent at Baseline)</title>
          <description>Adequate response defined that seated trough diastolic blood pressure was &lt;90 mmHg or decreased from reference baseline by &gt;=10 mmHg at 8 weeks</description>
          <population>Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Achieved an Adequate Response in Seated Trough Systolic Blood Pressure at 8 Weeks (0 Percent at Baseline)</title>
        <description>Adequate response defined that seated trough systolic blood pressure was &lt;140 mmHg or decreased from reference baseline by &gt;=20 mmHg at 8 weeks (0 percent at baseline)</description>
        <time_frame>8 weeks</time_frame>
        <population>Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
            <description>T40/A5 tablet, oral, once daily in the morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40 mg Monotherapy</title>
            <description>A5 capsule, oral, once daily in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Achieved an Adequate Response in Seated Trough Systolic Blood Pressure at 8 Weeks (0 Percent at Baseline)</title>
          <description>Adequate response defined that seated trough systolic blood pressure was &lt;140 mmHg or decreased from reference baseline by &gt;=20 mmHg at 8 weeks (0 percent at baseline)</description>
          <population>Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.5"/>
                    <measurement group_id="O2" value="58.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Optimal, Normal or High Normal Blood Pressure at 8 Weeks (0 Percent at Baseline)</title>
        <description>Optimal, normal, high normal blood pressure were defined as follows:
Optimal: Systolic blood pressure (SBP) &lt; 120 mmHg and diastolic blood pressure (DBP) &lt; 80 mmHg
Normal: SBP &gt;= 120 mmHg or DBP &gt;= 80 mmHg and SBP &lt; 130 mmHg and DBP &lt; 85 mmHg
High normal: SBP &gt;= 130 mmHg or DBP &gt;= 85 mmHg and SBP &lt; 140 mmHg and DBP &lt; 90 mmHg</description>
        <time_frame>8 weeks</time_frame>
        <population>Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
            <description>T40/A5 tablet, oral, once daily in the morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40 mg Monotherapy</title>
            <description>A5 capsule, oral, once daily in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Optimal, Normal or High Normal Blood Pressure at 8 Weeks (0 Percent at Baseline)</title>
          <description>Optimal, normal, high normal blood pressure were defined as follows:
Optimal: Systolic blood pressure (SBP) &lt; 120 mmHg and diastolic blood pressure (DBP) &lt; 80 mmHg
Normal: SBP &gt;= 120 mmHg or DBP &gt;= 80 mmHg and SBP &lt; 130 mmHg and DBP &lt; 85 mmHg
High normal: SBP &gt;= 130 mmHg or DBP &gt;= 85 mmHg and SBP &lt; 140 mmHg and DBP &lt; 90 mmHg</description>
          <population>Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Optimal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0"/>
                    <measurement group_id="O2" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.7"/>
                    <measurement group_id="O2" value="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1"/>
                    <measurement group_id="O2" value="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Relevant Abnormalities for Changes in Blood Pressure and Pulse Rate Due to Position Change, Seated Pulse Rate, Laboratory Parameters and ECG</title>
        <description>Clinical relevant abnormalities for changes in blood pressure and pulse rate due to position change, seated pulse rate, laboratory parameters and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.</description>
        <time_frame>First administration of randomised treatment to 24 hours post last dose of randomised treatment</time_frame>
        <population>Patients randomised to the double-blind treatment period who took at least one dose either of T40+A5 or T40 during the double-blind treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
            <description>T40/A5 tablet, oral, once daily in the morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40 mg Monotherapy</title>
            <description>A5 capsule, oral, once daily in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Relevant Abnormalities for Changes in Blood Pressure and Pulse Rate Due to Position Change, Seated Pulse Rate, Laboratory Parameters and ECG</title>
          <description>Clinical relevant abnormalities for changes in blood pressure and pulse rate due to position change, seated pulse rate, laboratory parameters and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.</description>
          <population>Patients randomised to the double-blind treatment period who took at least one dose either of T40+A5 or T40 during the double-blind treatment period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Arrhythmia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood potassium increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood pressure increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophil count increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Orthostatic hypotension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From drug administration until 24 hours after last drug administration</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
          <description>T40/A5 tablet, oral, once daily in the morning</description>
        </group>
        <group group_id="E2">
          <title>Telmisartan 40 mg Monotherapy</title>
          <description>A5 capsule, oral, once daily in the morning</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

